The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.
Open accessAbstract
The tridecamer d(A-A-T-G-G-T-A-A-A-A-T-G-G), which is complementary to 13 nucleotides of the 3'- and 5'-reiterated terminal sequences of Rous sarcoma virus 35S RNA, was added to chick embryo fibroblast tissue cultures infected with Rous sarcoma virus. Inhibition of virus production resulted. The inference emerges that the tridecamer and its counterpart with blocked 3'- and 5'-hydroxyl termini enter the chick fibroblast cells, hybridize with the terminal reiterated sequences at the 3' and 5' ends of the 35S RNA, and interfere with one or more steps involved in viral production and cell transformation. Likely sites of action are (i) the circularization step of the proviral DNA intermediate, and (ii) the initiation of translation, the latter being described in the following communication [Stephenson, M. L. & Zamecnik, P. C. (1978) Proc. Natl. Acad. Sci. USA 75, 285--288].
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Self-citationKawai, S., & Hanafusa, H. (1971) · Virology · doi:10.1016/0042-6822(71)90047-x · Cited by 399
Rous sarcoma virus genome is terminally redundant: the 5' sequence.
Haseltine, W. A., Maxam, A. M., & Gilbert, W. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.3.989 · Cited by 203
RNA Dependent DNA Polymerase Activity in Mammalian Cells
Scolnick, E. M., Aaronson, S. A., Todaro, G. J., & Parks, W. P. (1971) · Nature · doi:10.1038/229318a0 · Cited by 124
Rous sarcoma virus genome is terminally redundant: the 3' sequence.
Schwartz, D. E., Zamecnik, P. C., & Weith, H. L. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.3.994 · Cited by 124
Self-citationNucleotide sequence at the 5' terminus of the avian sarcoma virus genome.
Shine, J., Czernilofsky, A. P., Friedrich, R., Bishop, J. M., & Goodman, H. M. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.4.1473 · Cited by 100
Stoll, E., Billeter, M., Palmenberg, A. C., & Weissmann, C. (1977) · Cell · doi:10.1016/0092-8674(77)90185-4 · Cited by 78
Terminal redundancy and the origin of replication of Rous sarcoma virus RNA.
Coffin, J. M., & Haseltine, W. A. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.5.1908 · Cited by 60
Friedrich, R., Kung, H.-J., Baker, B., VARMUS, H. E., Goodman, H. M., & Bishop, J. M. (1977) · Virology · doi:10.1016/0042-6822(77)90345-2 · Cited by 54
Cited by
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
Rosi, N. L., Giljohann, D. A., Thaxton, C. S., Lytton-Jean, A. K. R., Han, M. S., & Mirkin, C. A. (2006) · Science · doi:10.1126/science.1125559 · Cited by 1,988
A general purpose RNA-cleaving DNA enzyme
Santoro, S. W., & Joyce, G. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4262 · Cited by 1,541
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
The chemical evolution of oligonucleotide therapies of clinical utility
Khvorova, A., & Watts, J. K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3765 · Cited by 1,216
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Overcoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Antisense technologies: Improvement through novel chemical modifications
Kurreck, J. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03555.x · Cited by 1,006
Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide.
Stephenson, M. L., & Zamecnik, P. C. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.285 · Cited by 906
Self-citationMetal Complexes as Photo- and Radiosensitizers
Ali, H., & van Lier, J. E. (1999) · Chemical Reviews · doi:10.1021/cr980439y · Cited by 848
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Knocking down disease: a progress report on siRNA therapeutics
Wittrup, A., & Lieberman, J. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3978 · Cited by 804
Antisense technology: an overview and prospectus
Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775
A BDNF autocrine loop in adult sensory neurons prevents cell death
Acheson, A., Conover, J. C., Fandl, J. P., DeChiara, T. M., Russell, M., Thadani, A., Squinto, S. P., Yancopoulos, G. D., & Lindsay, R. M. (1995) · Nature · doi:10.1038/374450a0 · Cited by 765
Molecular Targets for AIDS Therapy
Mitsuya, H., Yarchoan, R., & Broder, S. (1990) · Science · doi:10.1126/science.1699273 · Cited by 732
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
RNA-based therapeutics: an overview and prospectus
Zhu, Y., Zhu, L., Wang, X., & Jin, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05075-2 · Cited by 623
Therapeutic Targeting of Long Non-Coding RNAs in Cancer
Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 611
Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA
Braasch, D. A., & Corey, D. R. (2001) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00058-2 · Cited by 605
Designing Chemically Modified Oligonucleotides for Targeted Gene Silencing
Deleavey, G. F., & Damha, M. J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.07.011 · Cited by 589
Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents
Kleuss, C., Hescheler, J., Ewel, C., Rosenthal, W., Schultz, G., & Wittig, B. (1991) · Nature · doi:10.1038/353043a0 · Cited by 579
Therapeutic Antisense Oligonucleotides Are Coming of Age
Bennett, C. F. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041217-010829 · Cited by 579
Strategies, design, and chemistry in siRNA delivery systems
Dong, Y., Siegwart, D. J., & Anderson, D. G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.004 · Cited by 572
Izant, J. G., & Weintraub, H. (1984) · Cell · doi:10.1016/0092-8674(84)90050-3 · Cited by 549
Matsukura, M., Shinozuka, K., Zon, G., Mitsuya, H., Reitz, M., Cohen, J. S., & Broder, S. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7706 · Cited by 533
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Functional nucleic acid-based hydrogels for bioanalytical and biomedical applications
Li, J., Mo, L., Lu, C.-H., Fu, T., Yang, H.-H., & Tan, W. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00586h · Cited by 520
Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?
Yakubov, L. A., Deeva, E. A., Zarytova, V. F., Ivanova, E. M., Ryte, A. S., Yurchenko, L. V., & Vlassov, V. V. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6454 · Cited by 509
Silencing disease genes in the laboratory and the clinic
Watts, J. K., & Corey, D. R. (2012) · The Journal of Pathology · doi:10.1002/path.2993 · Cited by 470
Holt, J. T., Redner, R. L., & Nienhuis, A. W. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.963 · Cited by 464
Approaches for the sequence-specific knockdown of mRNA
Scherer, L. J., & Rossi, J. J. (2003) · Nature Biotechnology · doi:10.1038/nbt915 · Cited by 455
Chemical Modification of siRNAs for In Vivo Use
Behlke, M. A. (2008) · Oligonucleotides · doi:10.1089/oli.2008.0164 · Cited by 454
Lennox, K. A., & Behlke, M. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1206 · Cited by 453
Bielinska, A. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.11.2176 · Cited by 451
Role of RNase H in hybrid-arrested translation by antisense oligonucleotides.
Walder, R. Y., & Walder, J. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5011 · Cited by 450
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Progress in antisense technology
Crooke, S. T. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.104408 · Cited by 417
Goodchild, J. (1990) · Bioconjugate Chemistry · doi:10.1021/bc00003a001 · Cited by 406
Zamecnik, P. C., Goodchild, J., Taguchi, Y., & Sarin, P. S. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.12.4143 · Cited by 400
Self-citationMehta, M., Deeksha, Tewari, D., Gupta, G., Awasthi, R., Singh, H., Pandey, P., Chellappan, D. K., Wadhwa, R., Collet, T., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.028 · Cited by 397
Molecular Mechanisms of Antisense Oligonucleotides
Crooke, S. T. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0656 · Cited by 396
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013243 · Cited by 388
Gleave, M. E., & Monia, B. P. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1631 · Cited by 384
Phosphorothioate modified oligonucleotide–protein interactions
Crooke, S. T., Vickers, T. A., & Liang, X.-H. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa299 · Cited by 372
Wickstrom, E. L., Bacon, T. A., Gonzalez, A., Freeman, D. L., Lyman, G. H., & Wickstrom, E. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1028 · Cited by 369
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 331
Antisense technology: A review
Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 326
Therapeutic Oligonucleotides: State of the Art
Smith, C. I. E., & Zain, R. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021050 · Cited by 323
Letsinger, R. L., Zhang, G. R., Sun, D. K., Ikeuchi, T., & Sarin, P. S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.17.6553 · Cited by 304
Recent progress in non-native nucleic acid modifications
McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 300
Smith, C. C., Aurelian, L., Reddy, M. P., Miller, P. S., & Ts'o, P. O. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.9.2787 · Cited by 297
EDER, P. S., DeVINE, R. J., DAGLE, J. M., & WALDER, J. A. (1991) · Antisense Research and Development · doi:10.1089/ard.1991.1.141 · Cited by 293
Agrawal, S., Goodchild, J., Civeira, M. P., Thornton, A. H., Sarin, P. S., & Zamecnik, P. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7079 · Cited by 291
Self-citationTreating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Trawick, B. N., Daniher, A. T., & Bashkin, J. K. (1998) · Chemical Reviews · doi:10.1021/cr960422k · Cited by 281
Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment
Klasa, R. J., Gillum, A. M., Klem, R. E., & Frankel, S. R. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760220798 · Cited by 280
Selected organophosphorus compounds with biological activity. Applications in medicine
Demkowicz, S., Rachon, J., Daśko, M., & Kozak, W. (2016) · RSC Advances · doi:10.1039/c5ra25446a · Cited by 277
Anti-miRNA oligonucleotides: A comprehensive guide for design
Lima, J. F., Cerqueira, L., Figueiredo, C., Oliveira, C., & Azevedo, N. F. (2018) · RNA Biology · doi:10.1080/15476286.2018.1445959 · Cited by 276
Anfossi, G., Gewirtz, A. M., & Calabretta, B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3379 · Cited by 270
Wang, T., Upponi, J. R., & Torchilin, V. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 268
Oligonucleotide Therapies: The Past and the Present
Lundin, K. E., Gissberg, O., & Smith, C. I. E. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.070 · Cited by 267
Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267
RNA therapy: rich history, various applications and unlimited future prospects
Kim, Y.-K. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00757-5 · Cited by 264
Matsukura, M., Zon, G., Shinozuka, K., Robert-Guroff, M., Shimada, T., Stein, C. A., Mitsuya, H., Wong-Staal, F., Cohen, J. S., & Broder, S. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4244 · Cited by 262
Pharmacokinetics of Antisense Oligonucleotides
Agrawal, S., Temsamani, J., Galbraith, W., & Tang, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528010-00002 · Cited by 261
Targeted tumor therapy with the TGF-β2 antisense compound AP 12009
SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.002 · Cited by 195
Lipid-based nanoparticle formulations for small molecules and RNA drugs
Ickenstein, L. M., & Garidel, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1669558 · Cited by 193
“ASOs are dating back to the original work of Paul Zamecnik andMary Stephenson in the late 70s at the Harvard University [144].”
BackgroundCellular Uptake and Intracellular Trafficking of Antisense and siRNA Oligonucleotides
Juliano, R. L., Ming, X., & Nakagawa, O. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200377d · Cited by 181
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation
Mahas, A., Neal Stewart, C., & Mahfouz, M. M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.11.008 · Cited by 110
Involvement of long noncoding RNAs in diseases affecting the central nervous system
Pastori, C., & Wahlestedt, C. (2012) · RNA Biology · doi:10.4161/rna.20482 · Cited by 100
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
Association of 2' - 5' oligoribonucleotides
Kierzek, R., He, L., & Turner, D. H. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.7.1685 · Cited by 79
RNA-targeting strategies as a platform for ocular gene therapy
Kumar, S., Fry, L. E., Wang, J.-H., Martin, K. R., Hewitt, A. W., Chen, F. K., & Liu, G.-S. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101110 · Cited by 51
Analysis of therapeutic nucleic acids by capillary electrophoresis
Wei, B., Goyon, A., & Zhang, K. (2022) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2022.114928 · Cited by 50
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Bhagat, L., Putta, M. R., Wang, D., Yu, D., Lan, T., Jiang, W., Sun, Z., Wang, H., Tang, J. X., La Monica, N., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200113t · Cited by 20
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products
Decollibus, D. P., Searcy, J., Tivesten, A., Akhtar, N., Lindenberg, C., Abarrou, N., Pradhan, S., Fiandaca, M., Franklin, J., Govindan, G., et al. (2023) · Nucleic Acid Therapeutics · doi:10.1089/nat.2022.0073 · Cited by 17
Metadata
- Authors
- Zamecnik, P. C., & Stephenson, M. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1978-01
- Volume
- 75
- Issue
- 1
- Pages
- 280-284
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1990548509
- Cited by
- 1,792
- References
- 14
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.